Furmonertinib Plus Bevacizumab Boosts EGFR-TKI Resistance Outcomes
In a groundbreaking advance for patients grappling with the daunting challenge of leptomeningeal metastasis resistant to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), a...














